Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 383

1.

Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, Hatina J, Wolf D, Reimer D, Zeimet AG.

J Cancer Res Clin Oncol. 2018 Aug 6. doi: 10.1007/s00432-018-2725-2. [Epub ahead of print]

PMID:
30083818
2.

Treatment of Retained Fetal Membranes in the Mare-A Practitioner Survey.

Warnakulasooriya DN, Marth CD, McLeod JA, Hanlon DW, Krekeler N.

Front Vet Sci. 2018 Jun 19;5:128. doi: 10.3389/fvets.2018.00128. eCollection 2018.

3.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2018 May 5. doi: 10.1093/annonc/mdy160. [Epub ahead of print] No abstract available.

PMID:
29741577
4.

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.

Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C.

Oncotarget. 2018 Apr 3;9(25):17501-17511. doi: 10.18632/oncotarget.24770. eCollection 2018 Apr 3.

5.
6.

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2018 Apr;297(4):837-846. doi: 10.1007/s00404-018-4673-0. Epub 2018 Jan 22. Review. Erratum in: Arch Gynecol Obstet. 2018 Feb 14;:.

PMID:
29356953
7.

Front-line therapy of advanced epithelial ovarian cancer: standard treatment.

Marth C, Reimer D, Zeimet AG.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii36-viii39. doi: 10.1093/annonc/mdx450. Review.

PMID:
29232473
8.

Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.

Reimer D, Boesch M, Wolf D, Marth C, Sopper S, Hatina J, Altevogt P, Parson W, Hackl H, Zeimet AG.

Int J Cancer. 2018 Apr 15;142(8):1640-1651. doi: 10.1002/ijc.31186. Epub 2017 Dec 14.

PMID:
29194596
9.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
10.

Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.

Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, Siebert U.

J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.

PMID:
29091014
11.

Platinum or nonplatinum in recurrent ovarian cancer: that is the question.

Poveda A, Marth C.

Future Oncol. 2017 Oct;13(23s):11-16. doi: 10.2217/fon-2017-0317. Epub 2017 Oct 11. Review.

PMID:
29020823
12.

Managing relapsed ovarian cancer in a rapidly evolving landscape.

Poveda A, Marth C.

Future Oncol. 2017 Oct;13(23s):1. doi: 10.2217/fon-2017-0315. Epub 2017 Oct 11. No abstract available.

PMID:
29020820
13.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83. doi: 10.1093/annonc/mdx220. No abstract available.

PMID:
28881916
14.

A Unifying Synthesis Approach to the C18-, C19-, and C20-Diterpenoid Alkaloids.

Kou KGM, Kulyk S, Marth CJ, Lee JC, Doering NA, Li BX, Gallego GM, Lebold TP, Sarpong R.

J Am Chem Soc. 2017 Oct 4;139(39):13882-13896. doi: 10.1021/jacs.7b07706. Epub 2017 Sep 20.

15.

Innate immune genes in persistent mating-induced endometritis in horses.

Marth CD, Firestone SM, Hanlon D, Glenton LY, Browning GF, Young ND, Krekeler N.

Reprod Fertil Dev. 2018 Mar;30(3):533-545. doi: 10.1071/RD17157.

PMID:
28834688
16.

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS).

Zeimet AG, Mori H, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer C, Wimmer K, Zschocke J, Marth C.

Arch Gynecol Obstet. 2017 Jul;296(1):123-127. doi: 10.1007/s00404-017-4392-y. Epub 2017 May 16.

17.

Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria.

Oberaigner W, Geiger-Gritsch S, Edlinger M, Daniaux M, Knapp R, Hubalek M, Siebert U, Marth C, Buchberger W.

Breast. 2017 Jun;33:178-182. doi: 10.1016/j.breast.2017.04.002. Epub 2017 Apr 15.

PMID:
28419909
18.

L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.

Abdel Azim S, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C.

Int J Gynecol Pathol. 2017 Jul;36(4):356-363. doi: 10.1097/PGP.0000000000000338.

PMID:
28221216
19.

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.

McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010.

PMID:
28119296
20.

Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria.

Potz FL, Tomasch G, Polterauer S, Laky R, Marth C, Tamussino K.

Geburtshilfe Frauenheilkd. 2016 Dec;76(12):1325-1329. doi: 10.1055/s-0042-116493.

21.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA.

Eur J Cancer. 2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1.

PMID:
27914241
22.

Oestrous cycle-dependent equine uterine immune response to induced infectious endometritis.

Marth CD, Firestone SM, Glenton LY, Browning GF, Young ND, Krekeler N.

Vet Res. 2016 Nov 8;47(1):110.

23.

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.

Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4. Review.

PMID:
27821315
24.

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.

Colombo N, Hardy-Bessard AC, Ferrandina G, Marth C, Romero I.

Expert Rev Anticancer Ther. 2016 Nov;16(sup1):11-19. Review.

PMID:
27797622
25.

Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.

Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedermair A, Rössler J, Altevogt P, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 28;7(26):40221-40232. doi: 10.18632/oncotarget.9574.

26.

Marked improvement in the success rate of medical management of early pregnancy failure following the implementation of a novel institutional protocol and treatment guidelines: a follow-up study.

Colleselli V, Nell T, Bartosik T, Brunner C, Ciresa-Koenig A, Wildt L, Marth C, Seeber B.

Arch Gynecol Obstet. 2016 Nov;294(6):1265-1272. Epub 2016 Aug 23.

27.

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.

Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, Fiegl H, Marth C, Kimpel J, von Laer D.

Mol Ther Oncolytics. 2016 Sep 28;3:16021. eCollection 2016.

28.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.

N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.

29.

European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A.

Int J Gynecol Cancer. 2016 Sep;26(7):1354-63. doi: 10.1097/IGC.0000000000000767.

PMID:
27648648
30.

Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.

Borena W, Grünberger M, Widschwendter A, Kraxner KH, Marth E, Mayr P, Meier J, Ruth N, Guerrero AT, Marth C, Holm-von Laer D.

BMC Public Health. 2016 Aug 26;16:889. doi: 10.1186/s12889-016-3581-0.

31.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM.

Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18.

PMID:
27546885
32.

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.

Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG.

BMC Cancer. 2016 Aug 2;16:589. doi: 10.1186/s12885-016-2637-y.

33.

Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO).

Volgger BM, Windbichler GH, Zeimet AG, Graf AH, Bogner G, Angleitner-Boubenizek L, Rohde M, Denison U, Sliutz G, Fuith LC, Fuchs D, Marth C.

Ann Oncol. 2016 Sep;27(9):1740-6. doi: 10.1093/annonc/mdw248. Epub 2016 Jun 29.

PMID:
27358381
34.

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A.

J Clin Oncol. 2016 Jul 20;34(21):2516-25. doi: 10.1200/JCO.2015.66.0787. Epub 2016 Jun 6.

PMID:
27269942
35.

Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.

Abdel Azim S, Duggan-Peer M, Sprung S, Reimer D, Fiegl H, Soleiman A, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 14;7(24):37205-37214. doi: 10.18632/oncotarget.9291.

36.

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.

Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):147-149.

37.

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin N, Altevogt P, Marth C, Zeimet AG.

BMC Cancer. 2016 Feb 15;16:102. doi: 10.1186/s12885-016-2135-2.

38.

ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.

Radiother Oncol. 2015 Dec;117(3):559-81. doi: 10.1016/j.radonc.2015.11.013. Epub 2015 Dec 9.

39.

Network-analysis-guided synthesis of weisaconitine D and liljestrandinine.

Marth CJ, Gallego GM, Lee JC, Lebold TP, Kulyk S, Kou KG, Qin J, Lilien R, Sarpong R.

Nature. 2015 Dec 24;528(7583):493-8. doi: 10.1038/nature16440.

40.

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.

Int J Gynecol Cancer. 2016 Jan;26(1):2-30. doi: 10.1097/IGC.0000000000000609.

41.

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.

Ann Oncol. 2016 Jan;27(1):16-41. doi: 10.1093/annonc/mdv484. Epub 2015 Dec 2. Erratum in: Ann Oncol. 2017 Jul 1;28(suppl_4):iv167-iv168.

PMID:
26634381
42.

Deep sequencing of the uterine immune response to bacteria during the equine oestrous cycle.

Marth CD, Young ND, Glenton LY, Noden DM, Browning GF, Krekeler N.

BMC Genomics. 2015 Nov 14;16:934. doi: 10.1186/s12864-015-2139-3.

43.

Precancerous Lesions of the Cervix, Vulva and Vagina According to the 2014 WHO Classification of Tumors of the Female Genital Tract.

Reich O, Regauer S, Marth C, Schmidt D, Horn LC, Dannecker C, Menton M, Beckmann MW.

Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1018-1020. No abstract available.

44.

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.

Petru E, Singer CF, Polterauer S, Galid A, Schauer C, Klocker J, Seifert M, Reinthaller A, Benedicic C, Hubalek M, Hefler L, Marth C, Scholl-Firon T, Bogner G, Zeimet AG.

Wien Med Wochenschr. 2015 Oct;165(19-20):387-94. doi: 10.1007/s10354-015-0392-3. Epub 2015 Oct 15. Review.

PMID:
26471371
45.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.

PMID:
26419591
46.

The effect of EUSOMA certification on quality of breast cancer care.

van Dam PA, Tomatis M, Marotti L, Heil J, Wilson R, Rosselli Del Turco M, Mayr C, Costa A, Danei M, Denk A, Emons G, Friedrichs K, Harbeck N, Kiechle M, Koheler U, Kuemmel S, Maass N, Marth C, Prové A, Kimmig R, Rageth C, Regolo L, Salehi L, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Ponti A; eusomaDB Working Group:; eusomaDB Working Group.

Eur J Surg Oncol. 2015 Oct;41(10):1423-9. doi: 10.1016/j.ejso.2015.06.006. Epub 2015 Jun 24.

PMID:
26278019
47.

AGO Austria recommendations for genetic testing of patients with ovarian cancer.

Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG.

Wien Klin Wochenschr. 2015 Aug;127(15-16):652-4. doi: 10.1007/s00508-015-0814-7.

48.

The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.

Marth C, du Bois A, Schauer C, du Bois A, Casado A, Vergote I, del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool R, Taskiran C, Fehr M, Cibula D.

Int J Gynecol Cancer. 2015 Jul;25(6):1094-5. doi: 10.1097/IGC.0000000000000446. No abstract available.

PMID:
26098090
49.

European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.

du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I; member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT).

Int J Gynecol Cancer. 2015 Sep;25(7):1328-30. doi: 10.1097/IGC.0000000000000478.

PMID:
26067859
50.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499

Supplemental Content

Support Center